Gland Pharma Ltd
Gland Pharma Ltd (GLAND) last traded at ₹2,833, a market capitalisation of ₹46,739 crore, on a P/E of 40.7. Over the past 52 weeks the stock has ranged between ₹1,574 and ₹3,040. Gland Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,800 crore and net profit of ₹317 crore. The next scheduled event is an analyst meet on 26 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Gland Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Gland Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,800 cr, up 19.5% from ₹1,506 cr a year earlier. Net profit was ₹317 cr, up 47.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Operating profit | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% |
| Other income | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% |
| Net profit | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS (₹) | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gland Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 6,725 |
| Operating profit | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,751 |
| OPM % | 38% | 34% | 28% | 24% | 23% | 25% | 26% |
| Net profit | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS (₹) | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 62.35 | 68.49 |
TTM is the trailing twelve months to the most recent quarter.
Gland Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- 8%
- TTM
- 49%
- 10 Years
- %
- 5 Years
- -6%
- 3 Years
- 22%
- 1 Year
- 44%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 9%
- Last Year
- 11%
Gland Pharma Ltd shareholding pattern
Promoters held 51.77% at Jun 2026, broadly unchanged since Jun 2025. FIIs 8.74% and DIIs 30.44%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% |
| FIIs | 4.48% | 5.04% | 6.90% | 7.39% | 7.90% | 7.58% | 7.29% | 8.74% |
| DIIs | 35.37% | 34.80% | 33.27% | 32.86% | 32.63% | 32.99% | 33.36% | 30.44% |
| Public | 8.33% | 8.33% | 8.00% | 7.93% | 7.63% | 7.62% | 7.52% | 9.06% |
| No. of shareholders | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 | 94,578 | 91,500 | 1,08,266 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Gland Pharma Ltd events
The next scheduled event is an analyst meet on 26 Aug 2026.
- Analyst meetAnalyst/Institutional Investor Meetings
- Earnings resultsQ2FY27 earnings release
- OtherAppointment of Mr. Deepak Sapra as the new Chief Executive Officer
See the full results calendar for every Indian company reporting in the next 30 days.
Gland Pharma Ltd corporate filings
- Schedule of Investor MeetCompany Updatelow impact
Cruxal's analysis: Gland Pharma Ltd has issued an intimation regarding a scheduled investor meet. The…
Read the full analysis - Q1FY27 Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Gland Pharma Limited delivered a robust performance for Q1 FY27, reporting consolidated…
Read the full analysis - Appointment of Chief Executive Officer of the CompanyCompany Updatehigh impact
Cruxal's analysis: Gland Pharma Limited has announced the appointment of Mr. Deepak Sapra as its new Chief…
Read the full analysis - Newspaper Publication on Q1FY27 Financial ResultsCompany Updatelow impact
Cruxal's analysis: Gland Pharma Limited has formally notified the stock exchanges regarding the approval of…
Read the full analysis - Q1FY27 Earnings Call Audio recordingCompany Updatelow impact
Cruxal's analysis: Gland Pharma Limited has formally filed the audio recording of its earnings conference…
Read the full analysis - Schedule of Investor MeetsCompany Updatelow impact
Cruxal's analysis: Gland Pharma has issued an intimation regarding a schedule of investor meetings. This is…
Read the full analysis - Investor Presentation on Q1FY27 Financial ResultsCompany Updatehigh impact
Cruxal's analysis: Gland Pharma reported robust Q1 FY27 financial results with revenue from operations…
Read the full analysis - Press release on Q1FY27 Financial ResultsCompany Updatehigh impact
Cruxal's analysis: Gland Pharma Limited reported robust Q1 FY27 financial results with revenue from…
Read the full analysis - Unaudited Financial results for the quarter ended June 30, 2026Resulthigh impact
Cruxal's analysis: Gland Pharma Limited reported robust financial results for the quarter ended June 30…
Read the full analysis - Gland Pharma announces strategic CDMO partnership with a Global Pharmaceutical CompanyCompany Updatemedium impact
Cruxal's analysis: Gland Pharma has announced a strategic Contract Development and Manufacturing…
Read the full analysis - Gland Pharma announces strategic collaboration with Neuland Laboratories for sterile API ManufacturingCompany Updatemedium impact
Cruxal's analysis: Gland Pharma has entered into a strategic collaboration with Neuland Laboratories to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Gland Pharma Ltd
Cruxal reads every Gland Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.